Tu SM - Search Results

1

Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.

Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, Tu SM, Aparicio A, Troncoso P, Mohler J, Logothetis CJ. Efstathiou E, et al. Among authors: tu sm. Eur Urol. 2015 Jan;67(1):53-60. doi: 10.1016/j.eururo.2014.05.005. Epub 2014 May 29. Eur Urol. 2015. PMID: 24882673 Free PMC article. Clinical Trial.

2

Estramustine-related hypocalcemia in patients with prostate carcinoma and osteoblastic metastases.

Park DS, Vassilopoulou Sellin R, Tu S. Park DS, et al. Urology. 2001 Jul;58(1):105. doi: 10.1016/s0090-4295(01)01119-0. Urology. 2001. PMID: 11445494

3

Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer.

Siefker-Radtke AO, Millikan RE, Tu SM, Moore DF Jr, Smith TL, Williams D, Logothetis CJ. Siefker-Radtke AO, et al. Among authors: tu sm. J Clin Oncol. 2002 Mar 1;20(5):1361-7. doi: 10.1200/JCO.2002.20.5.1361. J Clin Oncol. 2002. PMID: 11870180 Clinical Trial.

4

Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma.

Pagliaro LC, Millikan RE, Tu SM, Williams D, Daliani D, Papandreou CN, Logothetis CJ. Pagliaro LC, et al. Among authors: tu sm. J Clin Oncol. 2002 Jul 1;20(13):2965-70. doi: 10.1200/JCO.2002.11.114. J Clin Oncol. 2002. PMID: 12089226 Clinical Trial.

5

Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate.

Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, Troncoso P, Logothetis CJ. Papandreou CN, et al. Among authors: tu sm. J Clin Oncol. 2002 Jul 15;20(14):3072-80. doi: 10.1200/JCO.2002.12.065. J Clin Oncol. 2002. PMID: 12118020 Clinical Trial.

6

Stem-cell origin of metastasis and heterogeneity in solid tumours.

Tu SM, Lin SH, Logothetis CJ. Tu SM, et al. Lancet Oncol. 2002 Aug;3(8):508-13. doi: 10.1016/s1470-2045(02)00820-3. Lancet Oncol. 2002. PMID: 12147437 Review.

7

Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features.

Tu SM, Reyes A, Maa A, Bhowmick D, Pisters LL, Pettaway CA, Lin SH, Troncoso P, Logothetis CJ. Tu SM, et al. Cancer. 2002 May 15;94(10):2610-7. doi: 10.1002/cncr.10546. Cancer. 2002. PMID: 12173328 Free article.

8

Targeting prostate cancer bone metastases.

Logothetis C, Tu SM, Navone N. Logothetis C, et al. Among authors: tu sm. Cancer. 2003 Feb 1;97(3 Suppl):785-8. doi: 10.1002/cncr.11130. Cancer. 2003. PMID: 12548576 Free article. No abstract available.

9

Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma.

Daliani DD, Assikis V, Tu SM, Papandreou CN, Pagliaro LC, Holtkamp T, Wang X, Thall PF, Logothetis CJ. Daliani DD, et al. Among authors: tu sm. Cancer. 2003 Feb 1;97(3):561-7. doi: 10.1002/cncr.11078. Cancer. 2003. PMID: 12548597 Free article. Clinical Trial.

10

Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II study.

Kim J, Millikan RE, Smith TL, Tu SM, Pagliaro LC, Logothetis CJ. Kim J, et al. Among authors: tu sm. Urol Oncol. 2003 Jan-Feb;21(1):21-6. doi: 10.1016/s1078-1439(02)00207-7. Urol Oncol. 2003. PMID: 12684123 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

198 results

Search Page

Filters